BioCentury
ARTICLE | Clinical News

CPI-613: Phase I data

June 2, 2014 7:00 AM UTC

An open-label, dose-escalation, U.S. Phase I trial in 24 patients with relapsed or refractory ALL showed that 500-2,250 mg/m 2 doses of IV CPI-613 plus cytarabine and mitoxantrone led to an ORR of 54%...